Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis

Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Robert T. Williams, Martin S. Tallman, Amer M. Zeidan, and Maximilian Stahl

Disclosures: A.M.Z. received research funding (institutional) from Celgene, Acceleron, Abbvie, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Jazz, Ariad, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Seattle Genetics, BeyondSpring, Trovagene, Ionis, Epizyme, and Takeda. A.M.Z received travel support for meetings from Pfizer, Novartis, and Trovagene. M.S.T. has received research funding from Abbvie, Cellerant, Orsenix, ADC Therapeutics, and Biosight. M.S.T. has received honoraria for advisory board membership from Abbvie, BioLineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, and Jazz Pharma. M.S.T. received patents and royalties from UpToDate. None of these relationships were related to the development of this manuscript. None of these relationships were related to the development of this manuscript. All other authors report no relevant disclosures/competing interests.

Contributions: JPB and MS designed the study, performed data extraction and wrote the initial draft of the manuscript; JPB, MS, SG, and RW performed data analysis; all authors interpreted data, critically reviewed and contributed on all subsequent drafts of the manuscript.